Why the study?
Does deanol improve symptoms in patients with tardive dyskinesia compared to placebo?
Population
14 patients with tardive dyskinesia (both inpatients and outpatients)
Comparison
Deanol acetamidobenzoate 2.0 g/day for four weeks vs Placebo
Design
RCT, crossover trial, double-blind
Follow-up
4 weeks
Authors
Loading...
Deanol is not superior to placebo for tardive dyskinesia; confirms lack of efficacy and supports avoiding its use in practice.
Does deanol improve symptoms in patients with tardive dyskinesia compared to placebo?
Deanol acetamidobenzoate is not superior to placebo in the treatment of tardive dyskinesia.
Patricia Penovich (1978) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: